Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients
Background: Breast cancer (BC) is the second most common cancer worldwide. MicroRNAs are a group of non-coding, single stranded RNAs of ~ 22 nucleotides, which regulate gene expression at the post-transcriptional level. Circulating miRNAs have been found as potential blood based predictive biomarker...
Gespeichert in:
| Veröffentlicht in: | Asian Pacific Journal of Cancer Prevention 2019-09, Vol.20 (9), p.2749-2755 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2755 |
|---|---|
| container_issue | 9 |
| container_start_page | 2749 |
| container_title | Asian Pacific Journal of Cancer Prevention |
| container_volume | 20 |
| creator | Kassem, Neemat M Makar, Wael S Kassem, Hebatallah A Talima, Soha Tarek, Mustafa Hesham, Hadeer El-Desouky, Mohamed A |
| description | Background: Breast cancer (BC) is the second most common cancer worldwide. MicroRNAs are a group of
non-coding, single stranded RNAs of ~ 22 nucleotides, which regulate gene expression at the post-transcriptional level.
Circulating miRNAs have been found as potential blood based predictive biomarkers. Purpose: we aim to evaluate
miR-34a and miR-125b to predict outcome from neoadjuvant chemotherapy in Egyptian BC patients. Methodology:
Quantitative assessment of plasma miR-34a and miR-125b expression was performed by qRT-PCR. Thirty nine
newly diagnosed locally advanced BC female patients with 10 age and sex matched healthy volunteers were included
in the study. Results: We performed ROC curve analysis to evaluate the diagnostic value for the miR-34a with
AUCs = 0.995, cutoff point of 2.57 sensitivity 97.4%, specificity 100%, PPV 100%, NPV 83.3% and accuracy 97.7%.
miR-125b had AUC = 0.68 and a cutoff point of 8.69 with sensitivity 66.7%, specificity 70.0%, PPV 90.6%, NPV
41.2% and accuracy 73.5%. miR-34a expression were significantly higher in BC patients compared to controls with p
value |
| doi_str_mv | 10.31557/apjcp.2019.20.9.2749 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6976833</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31554373</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3929-6eba8b3cbc97907e0b95affd4d098802d948615b6f29d3d2b6707f34ff7b0ad23</originalsourceid><addsrcrecordid>eNpVUdtKAzEUDKJ4_wQlP7A1m-xuNi9CXbxUChZR8C2cXLZGt9klqYX-valV0ZfJHJKZOWQQOsvJiOVlyS9geNPDiJJcJBgl4IXYQYe04FXGK_qy-4cfoKMY3wgpypqX--hg41Awzg7RunFBf3SwdH6OF-4xYwVg8OaL57RUGCKehX7h4uaF7z2e-BVEt7L4yvULCO82ROw8vp6vh6UDj6e9hq5b47FZgdfW4KtgIS5xs5kCnqUs65fxBO210EV7-n0eo-eb66fmLps-3E6a8TTTTFCRVVZBrZhWWnBBuCVKlNC2pjBE1DWhRhR1lZeqaqkwzFBVccJbVrQtVwQMZcfocus7fKiFNTplB-jkEFxafi17cPL_jXevct6vZCV4VTOWDMqtgQ59jMG2v9qcyK8u5Hh238zkposEMkHqIunO_wb_qn4-n30C5kqIjQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients</title><source>Freely Accessible Journals</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Kassem, Neemat M ; Makar, Wael S ; Kassem, Hebatallah A ; Talima, Soha ; Tarek, Mustafa ; Hesham, Hadeer ; El-Desouky, Mohamed A</creator><creatorcontrib>Kassem, Neemat M ; Makar, Wael S ; Kassem, Hebatallah A ; Talima, Soha ; Tarek, Mustafa ; Hesham, Hadeer ; El-Desouky, Mohamed A</creatorcontrib><description>Background: Breast cancer (BC) is the second most common cancer worldwide. MicroRNAs are a group of
non-coding, single stranded RNAs of ~ 22 nucleotides, which regulate gene expression at the post-transcriptional level.
Circulating miRNAs have been found as potential blood based predictive biomarkers. Purpose: we aim to evaluate
miR-34a and miR-125b to predict outcome from neoadjuvant chemotherapy in Egyptian BC patients. Methodology:
Quantitative assessment of plasma miR-34a and miR-125b expression was performed by qRT-PCR. Thirty nine
newly diagnosed locally advanced BC female patients with 10 age and sex matched healthy volunteers were included
in the study. Results: We performed ROC curve analysis to evaluate the diagnostic value for the miR-34a with
AUCs = 0.995, cutoff point of 2.57 sensitivity 97.4%, specificity 100%, PPV 100%, NPV 83.3% and accuracy 97.7%.
miR-125b had AUC = 0.68 and a cutoff point of 8.69 with sensitivity 66.7%, specificity 70.0%, PPV 90.6%, NPV
41.2% and accuracy 73.5%. miR-34a expression were significantly higher in BC patients compared to controls with p
value <0.001*. Also, miR-34a expression level was significantly higher in patients with progressive disease with P value
=0.03*. However, miR-125b expression levels were insignificantly higher in responsive patients with p value = 0.2.
Conclusion: miRNAs are crucial candidates for novel molecular targeted therapies due to their capability to regulate
numerous genes in molecular pathways. Our data suggest that circulating miR-34a and miR-125b expression levels
could be promising highly accurate non-invasive biomarkers in diagnosing BCs. miR-34a can predict chemotherapeutic
resistance associated with higher expression levels in non-responsive patients.</description><identifier>ISSN: 2476-762X</identifier><identifier>ISSN: 1513-7368</identifier><identifier>EISSN: 2476-762X</identifier><identifier>DOI: 10.31557/apjcp.2019.20.9.2749</identifier><identifier>PMID: 31554373</identifier><language>eng</language><publisher>Thailand: West Asia Organization for Cancer Prevention</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers, Tumor ; Breast Neoplasms - blood ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Carcinoma, Ductal, Breast - blood ; Carcinoma, Ductal, Breast - drug therapy ; Carcinoma, Ductal, Breast - genetics ; Carcinoma, Ductal, Breast - pathology ; Carcinoma, Lobular - blood ; Carcinoma, Lobular - drug therapy ; Carcinoma, Lobular - genetics ; Carcinoma, Lobular - pathology ; Circulating MicroRNA - blood ; Circulating MicroRNA - genetics ; Egypt ; Female ; Follow-Up Studies ; Gene Expression Regulation, Neoplastic ; Humans ; MicroRNAs - blood ; MicroRNAs - genetics ; Middle Aged ; Neoadjuvant Therapy ; Prognosis</subject><ispartof>Asian Pacific Journal of Cancer Prevention, 2019-09, Vol.20 (9), p.2749-2755</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3929-6eba8b3cbc97907e0b95affd4d098802d948615b6f29d3d2b6707f34ff7b0ad23</citedby><orcidid>0000-0002-6033-6839</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976833/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976833/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,27933,27934,53800,53802</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31554373$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kassem, Neemat M</creatorcontrib><creatorcontrib>Makar, Wael S</creatorcontrib><creatorcontrib>Kassem, Hebatallah A</creatorcontrib><creatorcontrib>Talima, Soha</creatorcontrib><creatorcontrib>Tarek, Mustafa</creatorcontrib><creatorcontrib>Hesham, Hadeer</creatorcontrib><creatorcontrib>El-Desouky, Mohamed A</creatorcontrib><title>Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients</title><title>Asian Pacific Journal of Cancer Prevention</title><addtitle>Asian Pac J Cancer Prev</addtitle><description>Background: Breast cancer (BC) is the second most common cancer worldwide. MicroRNAs are a group of
non-coding, single stranded RNAs of ~ 22 nucleotides, which regulate gene expression at the post-transcriptional level.
Circulating miRNAs have been found as potential blood based predictive biomarkers. Purpose: we aim to evaluate
miR-34a and miR-125b to predict outcome from neoadjuvant chemotherapy in Egyptian BC patients. Methodology:
Quantitative assessment of plasma miR-34a and miR-125b expression was performed by qRT-PCR. Thirty nine
newly diagnosed locally advanced BC female patients with 10 age and sex matched healthy volunteers were included
in the study. Results: We performed ROC curve analysis to evaluate the diagnostic value for the miR-34a with
AUCs = 0.995, cutoff point of 2.57 sensitivity 97.4%, specificity 100%, PPV 100%, NPV 83.3% and accuracy 97.7%.
miR-125b had AUC = 0.68 and a cutoff point of 8.69 with sensitivity 66.7%, specificity 70.0%, PPV 90.6%, NPV
41.2% and accuracy 73.5%. miR-34a expression were significantly higher in BC patients compared to controls with p
value <0.001*. Also, miR-34a expression level was significantly higher in patients with progressive disease with P value
=0.03*. However, miR-125b expression levels were insignificantly higher in responsive patients with p value = 0.2.
Conclusion: miRNAs are crucial candidates for novel molecular targeted therapies due to their capability to regulate
numerous genes in molecular pathways. Our data suggest that circulating miR-34a and miR-125b expression levels
could be promising highly accurate non-invasive biomarkers in diagnosing BCs. miR-34a can predict chemotherapeutic
resistance associated with higher expression levels in non-responsive patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers, Tumor</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - pathology</subject><subject>Carcinoma, Ductal, Breast - blood</subject><subject>Carcinoma, Ductal, Breast - drug therapy</subject><subject>Carcinoma, Ductal, Breast - genetics</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Carcinoma, Lobular - blood</subject><subject>Carcinoma, Lobular - drug therapy</subject><subject>Carcinoma, Lobular - genetics</subject><subject>Carcinoma, Lobular - pathology</subject><subject>Circulating MicroRNA - blood</subject><subject>Circulating MicroRNA - genetics</subject><subject>Egypt</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Humans</subject><subject>MicroRNAs - blood</subject><subject>MicroRNAs - genetics</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Prognosis</subject><issn>2476-762X</issn><issn>1513-7368</issn><issn>2476-762X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUdtKAzEUDKJ4_wQlP7A1m-xuNi9CXbxUChZR8C2cXLZGt9klqYX-valV0ZfJHJKZOWQQOsvJiOVlyS9geNPDiJJcJBgl4IXYQYe04FXGK_qy-4cfoKMY3wgpypqX--hg41Awzg7RunFBf3SwdH6OF-4xYwVg8OaL57RUGCKehX7h4uaF7z2e-BVEt7L4yvULCO82ROw8vp6vh6UDj6e9hq5b47FZgdfW4KtgIS5xs5kCnqUs65fxBO210EV7-n0eo-eb66fmLps-3E6a8TTTTFCRVVZBrZhWWnBBuCVKlNC2pjBE1DWhRhR1lZeqaqkwzFBVccJbVrQtVwQMZcfocus7fKiFNTplB-jkEFxafi17cPL_jXevct6vZCV4VTOWDMqtgQ59jMG2v9qcyK8u5Hh238zkposEMkHqIunO_wb_qn4-n30C5kqIjQ</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Kassem, Neemat M</creator><creator>Makar, Wael S</creator><creator>Kassem, Hebatallah A</creator><creator>Talima, Soha</creator><creator>Tarek, Mustafa</creator><creator>Hesham, Hadeer</creator><creator>El-Desouky, Mohamed A</creator><general>West Asia Organization for Cancer Prevention</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6033-6839</orcidid></search><sort><creationdate>20190901</creationdate><title>Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients</title><author>Kassem, Neemat M ; Makar, Wael S ; Kassem, Hebatallah A ; Talima, Soha ; Tarek, Mustafa ; Hesham, Hadeer ; El-Desouky, Mohamed A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3929-6eba8b3cbc97907e0b95affd4d098802d948615b6f29d3d2b6707f34ff7b0ad23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers, Tumor</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - pathology</topic><topic>Carcinoma, Ductal, Breast - blood</topic><topic>Carcinoma, Ductal, Breast - drug therapy</topic><topic>Carcinoma, Ductal, Breast - genetics</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Carcinoma, Lobular - blood</topic><topic>Carcinoma, Lobular - drug therapy</topic><topic>Carcinoma, Lobular - genetics</topic><topic>Carcinoma, Lobular - pathology</topic><topic>Circulating MicroRNA - blood</topic><topic>Circulating MicroRNA - genetics</topic><topic>Egypt</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Humans</topic><topic>MicroRNAs - blood</topic><topic>MicroRNAs - genetics</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kassem, Neemat M</creatorcontrib><creatorcontrib>Makar, Wael S</creatorcontrib><creatorcontrib>Kassem, Hebatallah A</creatorcontrib><creatorcontrib>Talima, Soha</creatorcontrib><creatorcontrib>Tarek, Mustafa</creatorcontrib><creatorcontrib>Hesham, Hadeer</creatorcontrib><creatorcontrib>El-Desouky, Mohamed A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Asian Pacific Journal of Cancer Prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kassem, Neemat M</au><au>Makar, Wael S</au><au>Kassem, Hebatallah A</au><au>Talima, Soha</au><au>Tarek, Mustafa</au><au>Hesham, Hadeer</au><au>El-Desouky, Mohamed A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients</atitle><jtitle>Asian Pacific Journal of Cancer Prevention</jtitle><addtitle>Asian Pac J Cancer Prev</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>20</volume><issue>9</issue><spage>2749</spage><epage>2755</epage><pages>2749-2755</pages><issn>2476-762X</issn><issn>1513-7368</issn><eissn>2476-762X</eissn><abstract>Background: Breast cancer (BC) is the second most common cancer worldwide. MicroRNAs are a group of
non-coding, single stranded RNAs of ~ 22 nucleotides, which regulate gene expression at the post-transcriptional level.
Circulating miRNAs have been found as potential blood based predictive biomarkers. Purpose: we aim to evaluate
miR-34a and miR-125b to predict outcome from neoadjuvant chemotherapy in Egyptian BC patients. Methodology:
Quantitative assessment of plasma miR-34a and miR-125b expression was performed by qRT-PCR. Thirty nine
newly diagnosed locally advanced BC female patients with 10 age and sex matched healthy volunteers were included
in the study. Results: We performed ROC curve analysis to evaluate the diagnostic value for the miR-34a with
AUCs = 0.995, cutoff point of 2.57 sensitivity 97.4%, specificity 100%, PPV 100%, NPV 83.3% and accuracy 97.7%.
miR-125b had AUC = 0.68 and a cutoff point of 8.69 with sensitivity 66.7%, specificity 70.0%, PPV 90.6%, NPV
41.2% and accuracy 73.5%. miR-34a expression were significantly higher in BC patients compared to controls with p
value <0.001*. Also, miR-34a expression level was significantly higher in patients with progressive disease with P value
=0.03*. However, miR-125b expression levels were insignificantly higher in responsive patients with p value = 0.2.
Conclusion: miRNAs are crucial candidates for novel molecular targeted therapies due to their capability to regulate
numerous genes in molecular pathways. Our data suggest that circulating miR-34a and miR-125b expression levels
could be promising highly accurate non-invasive biomarkers in diagnosing BCs. miR-34a can predict chemotherapeutic
resistance associated with higher expression levels in non-responsive patients.</abstract><cop>Thailand</cop><pub>West Asia Organization for Cancer Prevention</pub><pmid>31554373</pmid><doi>10.31557/apjcp.2019.20.9.2749</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-6033-6839</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2476-762X |
| ispartof | Asian Pacific Journal of Cancer Prevention, 2019-09, Vol.20 (9), p.2749-2755 |
| issn | 2476-762X 1513-7368 2476-762X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6976833 |
| source | Freely Accessible Journals; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor Breast Neoplasms - blood Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Carcinoma, Ductal, Breast - blood Carcinoma, Ductal, Breast - drug therapy Carcinoma, Ductal, Breast - genetics Carcinoma, Ductal, Breast - pathology Carcinoma, Lobular - blood Carcinoma, Lobular - drug therapy Carcinoma, Lobular - genetics Carcinoma, Lobular - pathology Circulating MicroRNA - blood Circulating MicroRNA - genetics Egypt Female Follow-Up Studies Gene Expression Regulation, Neoplastic Humans MicroRNAs - blood MicroRNAs - genetics Middle Aged Neoadjuvant Therapy Prognosis |
| title | Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T13%3A42%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20miR-34a%20and%20miR-125b%20as%20Promising%20non%20Invasive%20Biomarkers%20in%20Egyptian%20Locally%20Advanced%20Breast%20Cancer%20Patients&rft.jtitle=Asian%20Pacific%20Journal%20of%20Cancer%20Prevention&rft.au=Kassem,%20Neemat%20M&rft.date=2019-09-01&rft.volume=20&rft.issue=9&rft.spage=2749&rft.epage=2755&rft.pages=2749-2755&rft.issn=2476-762X&rft.eissn=2476-762X&rft_id=info:doi/10.31557/apjcp.2019.20.9.2749&rft_dat=%3Cpubmed_cross%3E31554373%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31554373&rfr_iscdi=true |